➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Moodys
Medtronic
McKesson
Johnson and Johnson

Last Updated: September 23, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,057,811

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,057,811 protect, and when does it expire?

Patent 8,057,811 protects VERSACLOZ and is included in one NDA.

This patent has six patent family members in six countries.

Summary for Patent: 8,057,811
Title:Stable clozapine suspension formulation
Abstract: A physicochemically stable aqueous composition including clozapine suspension.
Inventor(s): Surman; Peter William (Auckland, NZ), Ferguson; Sharon (Auckland, NZ), Mak; Wai Bik (Auckland, NZ), McLeod; Andrew Douglas (Auckland, NZ)
Assignee: Douglas Pharmaceuticals Limited (Auckland, NZ)
Application Number:10/561,930
Patent Claim Types:
see list of patent claims
 

Drugs Protected by US Patent 8,057,811

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Tasman Pharma VERSACLOZ clozapine SUSPENSION;ORAL 203479-001 Feb 6, 2013 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,057,811

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
New Zealand527142Jul 23, 2003
PCT Information
PCT FiledJuly 22, 2004PCT Application Number:PCT/NZ2004/000158
PCT Publication Date:January 27, 2005PCT Publication Number: WO2005/007168

International Family Members for US Patent 8,057,811

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2004257556   Start Trial
Canada 2532648   Start Trial
European Patent Office 1646393   Start Trial
Spain 2436213   Start Trial
New Zealand 527142   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
AstraZeneca
Medtronic
Express Scripts
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.